NEWS
SUBSCRIBER SEARCH (Requires Login)
  NEW DRUGS
  MARKETED DRUGS
  COMPANY
  TARGETS IN ONCOLOGY
  NEWS SUMMARIES
  COMBINATION TRIALS

Latest Updates

October 2011 New Drug Updates and Additions

Designation

Brand Name

Generic Name

4SC-201, BYK408740

 

Resminostat

HuLuc63, BMS-901608

 

Elotuzumab

Antibody 806, ch806, ABT-806

 

 

ADXS-HPV, ADXS11-001, Lm-LLO-E7

Lovaxin C

 

ADXS31-164, ADXS-HEr2

Lovaxin B

 

ANX-514, formerly SDP-014

 

 

AT001, r84

 

 

APN311, ch14.18

 

 

APN411

 

 

APN401

 

 

Adult stem cells

MultiStem

 

CVAC-301, formerly Panvac-VF

 

Familmarev/inalimarev

Bay 73-4506

 

Regorafenib

SHY03757, SH-Y03757A, ZK-219477, ZK219477, ZK-epothilone, BAY86-5302

ZK-EPO

Sagopilone

BiovaxID

 

 

CPX-351

 

Cytarabine:daunorubicin

CNTO 95, CNTO95

 

Intetumumab

COTI-2

 

 

AT-406, Debio 1143

 

 

APC8024, BA7072, DN24-02

Neuvenge

Lapuleucel-T

LY2181308, ISIS-23722, ISIS 23722

 

 

 

 

Defibrotide

ICT-107

 

 

huN901-DM1, BB-10901TAP, BB-10901, IMGN901

 

Lorvotuzumab mertansine

Y90 MAb LL2, 90Y-hLL2

LymphoCide Y-90

Epratuzumab

IMMU-106, hA20, hCD20

 

Veltuzumab

INK1117

 

 

CP-675,206, CP-675, CP-675206

 

Tremelimumab (formerly ticilimumab)

AP23573, MK-8669

 

Ridaforolimus (formerly deforolimus)

MK2206, MK-2206

 

 

L-BLP25, BLP-25 (formerly BP1-7-KLH), EMD531444

Stimuvax

Emepepimut-S

MIP-120T, Ultratrace MIBG

Azedra, Ultratrace iobenguane I-131

Iobenguane I 131

MORAb-003

 

Farletuzumab

3G4

Tarvacin

Bavituximab

PSMA ADC

 

 

HKI-272

 

Neratinib

TLN-4601, ECO-04601, ECO-4601, MW 462

 

 

INXN 2001/INX1001, Ad-RTS-IL-12, ZIN ATI-001

 

 

  

Home   |    Freelance Opportunities   |   New Medicine   |   Site Map   |  Order/Inquiry   
SUBSCRIBER SEARCH:   NEW DRUG   |   MARKETED DRUG   |   COMPANY   |   TARGETS IN ONCOLOGY  

NEW MEDICINE, INC.
P.O. BOX 909, LAKE FOREST, CA 92609
PHONE:  1-949-830-0448     FAX:  1-949-830-0887
INFO@NEWMEDINC.COM